Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03342742
Other study ID # 17-1327
Secondary ID R03DK118215
Status Completed
Phase N/A
First received
Last updated
Start date June 4, 2018
Est. completion date October 13, 2020

Study information

Verified date February 2022
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed research will determine the feasibility of delivering two behavioral weight loss interventions for 1 year in adults with autosomal dominant polycystic kidney disease (ADPKD) who are overweight or obese. The study will also compare these two interventions in terms of safety, acceptability, and tolerability. Last, this pilot trial will provide initial insight into a) biological changes and b) changes in kidney growth with each of the two weight loss interventions.


Description:

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by development and continued growth of numerous fluid-filled renal cysts that ultimately result in renal failure. Similar to the general population, the prevalence of overweight and obesity have been rising in ADPKD patients, effecting about two-thirds of individuals. Surprisingly, the role of obesity in ADPKD progression is currently unknown. The investigators have novel preliminary data that overweight and obesity are independently associated with substantially faster kidney growth in ADPKD patients. Furthermore, in rodent models of ADPKD, mild-to-moderate food restriction profoundly slows cyst growth and maintains renal function via mechanisms including AMPK-activated kinase pathway activation and suppression of mammalian target of rapamycin/S6 kinase signaling and insulin-like growth factor-1 levels. Collectively, these data suggest that dietary restriction regimens may slow ADPKD progression. Accordingly, the primary aim is to determine the feasibility of delivering a 1 year behavioral weight loss intervention program in 30 overweight/obese adults with ADPKD, based on either daily caloric restriction (DCR) or intermittent fasting (IMF), with a similar (~34%) targeted weekly energy deficit. A key secondary goal is to evaluate safety, acceptability, and tolerability of IMF in ADPKD versus DCR. Last, the third exploratory aim is to a) obtain mechanistic insight into biological pathways that may be altered and b) provide initial insight into any changes in total kidney volume by magnetic resonance imaging with IMF and/or DCR.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date October 13, 2020
Est. primary completion date October 13, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Aged 18-65 years 2. ADPKD diagnosis based on the modified Pei-Ravine criteria 3. BMI 25-45 kg/m^2 4. Normal to mildly declined renal function with an estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 by the CKD-EPI equation 5. Access to the internet with video chat capabilities 6. No plans for extended travel (>2 weeks) during the 3 month intesive period 7. Not currently participating in another interventional study or weight loss program 8. Ability to provide informed consent Exclusion Criteria: 1. Diabetes mellitus (diagnosis or fasting glucose >126 mg/dL or Hemoglobin A1C >6.5%) 2. Current nicotine use or history of use in the past 12 months 3. Alcohol or substance abuse (self-report or undergoing treatment) 4. History of hospitalization or major surgery within the last 3 months 5. Untreated dyslipidemia (low density lipoprotein cholesterol > 190 mg/dL or triglycerides >400 mg/dL) 6. Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg) 7. Pregnancy, lactation, or unwillingness to use adequate birth control 8. Cardiovascular disease, peripheral vascular disease, cerebrovascular disease, significant pulmonary or gastrointestinal disease (described below), cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis) 9. Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal PVC's, frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects 10. Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, ulcerative colitis, chronic diarrhea, or active gallbladder disease 11. Significant pulmonary disorders including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma 12. Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants; Study M.D. will be consulted as needed; antibiotics started during the intervention period are not an exclusion); regular use of obesity pharmacotherapeutic agents within the last 6 month 13. History of clinically diagnosed eating disorder including anorexia nervosa, bulimia, binge eating disorder 14. Weight loss >5% in past 3 months for any reason except post-partum weight loss; weight gain >5% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study. 15. Untreated hyper- or hyperthyroidism (TSH outside of normal range for laboratory or history of uncontrolled thyroid disorder). History of thyroid disorder or current thyroid disease treated with stable medication regimen for at least 6 months in acceptable. 16. Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. 17. History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions. 18. Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Weight Loss
Weight loss behavioral intervention via one of two strategies.

Locations

Country Name City State
United States Kristen Nowak Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility to Enroll and Retain Participants Numbers of individuals pre-screened Through study completion, an expected duration of 18 months
Primary Feasibility to Enroll Participants Numbers of individuals screened Through study completion, an expected duration of 18 months
Primary Feasibility to Retain Participants Numbers of individuals enrolled Through study completion, an expected duration of 18 months
Primary Feasibility to Retain Participants Numbers of individuals retained Through study completion, an expected duration of 18 months
Primary Percent Change From Baseline Body Weight (Weight Loss) Measurement of body weight pre to post intervention in each group Baseline, 12 weeks, and 1 year
Secondary Safety and Tolerability, Measured as Adverse Events Number of participants with treatment-related adverse events in each group as evaluated by monthly phone questionnaire 1 year
Secondary Quality of Life Scores at Baseline Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome. Baseline
Secondary Quality of Life Scores at 12 Weeks Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome. 12 Weeks
Secondary Quality of Life Scores at 1 Year Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome. 1 Year
Secondary Mood at Baseline Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores for the Vigor scale range from 0 to 32, with higher scores for indicating a better outcome. Possible scores for the fatigue scale range from 0 to 28 with higher scores indicating a worse outcome. Baseline
Secondary Mood at 12 Weeks Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome. 12 Weeks
Secondary Mood at 1 Year Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome. 1 Year
Secondary Change in Energy Intake Self-reported energy intake Baseline, 12 weeks and 1 year
Secondary Change in Macronutrient Intake Self-reported macronutrient intake Baseline, 12 weeks and 1 year
Secondary Serum Insulin-like Growth Factor-1 Levels at Baseline Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group Baseline
Secondary Serum Insulin-like Growth Factor-1 Levels at 12 Weeks Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group 12 Weeks
Secondary Serum Insulin-like Growth Factor-1 Levels at 1 Year Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group 1 Year
Secondary Insulin-like Growth Factor Binding Protein-1 Levels at Baseline Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group Baseline
Secondary Insulin-like Growth Factor Binding Protein-1 Levels at 12 Weeks Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group 12 Weeks
Secondary Insulin-like Growth Factor Binding Protein-1 Levels at 1 Year Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group 1 Year
Secondary Change in PBMC Ratio of pS6K/s6K Ratio of protein expression of phosphorylated S6K to S6K peripheral blood mononuclear cell protein expression of S6 kinase (S6K) in each group. Baseline and 1 year
Secondary Change in PBMC pAMPK/AMPK Expression Ratio of peripheral blood mononuclear cell protein expression of phosphorylated AMP-activated kinase (AMPK) to AMPK in each group Baseline and 1 year
Secondary Percent Change in Total Kidney Volume by Magnetic Resonance Imaging (MRI) Percent change from baseline in height adjusted total kidney volume by MRI in each group Baseline and 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Completed NCT04363554 - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Completed NCT03687554 - Effect of Venglustat in Patients With Renal Impairment Phase 1
Terminated NCT03523728 - A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients Phase 2/Phase 3
Completed NCT00565097 - Lanreotide as Treatment of Polycystic Livers Phase 2/Phase 3
Completed NCT00410007 - The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT02251275 - Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT01559363 - A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 1/Phase 2
Completed NCT02903511 - Feasibility Study of Metformin Therapy in ADPKD Phase 2
Completed NCT00456365 - Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Recruiting NCT05510115 - Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT02494141 - Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD Phase 4
Completed NCT04407481 - PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Completed NCT02847624 - Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Completed NCT02656017 - Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT04023214 - The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
Terminated NCT01589705 - The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease N/A
Completed NCT00426153 - Octreotide in Severe Polycystic Liver Disease Phase 2/Phase 3
Completed NCT04534985 - Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease N/A